Merck Raises EPS Outlook After Q2 Earnings
Merck reported better-than-expected second-quarter 2016 results before markets opened Friday morning.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 203
Bristol-Myers Earnings Don’t Appear to Be Enough for Investors
Bristol-Myers Squibb released a better-than-expected second-quarter earnings report before the markets opened on Thursday.
How Celgene Won With This Earnings Report
Overall, investors were content after Celgene reported its second-quarter financial results, with wins on both the top and bottom lines.
What to Look for in Amgen Earnings
Amgen is expected to report its second-quarter financial results after the markets close on Wednesday. Will it go the same way as Gilead Sciences did earlier this week?
Short Sellers Get Selective on Major Pharma
The short interest data have been released for the July 15 settlement date. For the selected pharmaceutical stocks, short interest was mixed.
JPMorgan Bullish on Biotech: 3 Top Picks to Buy Now
A new JPMorgan research report says it time to buy the health care sector and sell consumer staples, which have run hard this year.
Major Biotechs See Increased Short Interest Bets
The short interest data are out for the July 15 settlement date. Short interest increased across many of these selected biotech stocks.
Why Analysts Are Thinking M&A Is Back on the Table for Gilead
Overall, the Gilead Sciences report was not good and investors took to dumping the stock. On the other hand, this could provide a buying opportunity since shares are just off of their 52-week lows.
Why Eli Lilly Earnings Are So Dynamic
As one of the largest pharmaceutical companies on the street, Eli Lilly helps to set the tempo for the industry. Currently the company is in the middle of a very dynamic product launch.
Top Analyst Thinks Big Pharmaceutical Stocks Will Outperform the Rest of 2016
SunTrust Robinson Humphrey feels that the major pharmaceutical companies will outperform the rest of the year, and they cite new products, attractive dividends and solid performance as positives.
Why Analysts Were Not Satisfied With Gilead Earnings
Although Gilead Sciences is one of the world’s leading biotech companies, an earnings beat in its latest report was not enough to satisfy investors.
What to Expect From Gilead Sciences Earnings
Gilead Sciences is scheduled to release its second-quarter financial results after the markets close on Monday.
UnitedHealth Up 22%, Leads Dow in 2016
One key reason UnitedHealth has done well is that it has managed the downward pressure Obamacare has put on may insurance firms.
Is This the Turning Point Puma Biotech Investors Have Waited For?
Puma Biotechnology watched its shares make a handy gain on Friday morning after the firm released updated results from its late-stage breast cancer trial.
Why the Relypsa Merger Is a Great Idea
Relypsa made a splash in the markets on Thursday morning after the company announced an acquisition agreement.